The therapeutic use of Дикаин (Tetracaine) is to provide concentrated local analgesia—a temporary state of numbness—across key clinical domains, offering symptomatic support for otherwise painful procedures. As an established topical anesthetic, it is commonly used in situations involving localized discomfort, supporting additional management where appropriate, a role considered relevant across clinical domains.

The medication is applied to ease symptoms related to inflammatory or irritative states and procedural pain. Its therapeutic domains include addressing symptoms during ocular procedures, providing relief for minor clinical interventions such as dermatological procedures or intravenous access, and managing symptoms associated with major regional procedures like spinal anesthesia. This agent assists with maintaining functional stability during episodes of heightened discomfort. The overall benefit is that it helps manage pain that interferes with daily comfort and supports general well-being during symptomatic phases.

Quick Fact: Symptom Management
A therapeutic benefit	Provides support that helps ease the overall symptom burden by inducing concentrated numbness.
Target Symptoms	Acute ocular pain, sharp procedural pain, and localized discomfort during minor interventions.
Key Use Scenario	Applied in clinical settings that involve acute or disruptive symptom patterns, often requiring short-term symptomatic assistance.

Regulatory References

1. FDA DailyMed Overview

Eligibility Map: Who can and cannot use Дикаин (Tetracaine)

Official regulatory documents define strict population-based eligibility for Tetracaine, detailing who is permitted to use the medicine and under what conditions.

Eligibility Status	Defined Population (Official Regulatory Findings)
Absolute Contraindication	Patients with a known history of hypersensitivity or allergic reaction to Tetracaine or other amino-ester type anesthetics.
Established Use (All Ages)	Adults, geriatric patients, and pediatric patients (Safety and efficacy are established across all these age groups).
Restricted Use (Pregnancy)	Pregnant women (Use is restricted due to the lack of adequate and well-controlled studies; use is permitted only if the potential benefit justifies the potential risk).
Restricted Use (Lactation)	Lactating women (Use is restricted, requiring consideration of potential adverse effects on the breastfed child).
Conditional Use (Comorbidities)	Patients with pre-existing cardiac disease or liver disease (Caution is required due to the potential for systemic adverse effects and metabolic concerns).
Prohibited Mode of Use	Patient self-administration (The drug is restricted to application by or under the direct supervision of a healthcare provider).
Prohibited Duration of Use	Chronic or prolonged use (The medicine is not eligible for long-term use due to the risk of severe tissue damage).

This structure ensures that the medicine is primarily eligible for all standard age groups, but only when administered in a controlled, clinical setting for short durations, while strictly excluding individuals with drug hypersensitivity.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Дикаин (Tetracaine) based on its local anesthetic classification and metabolic pathway, focusing on additive toxicity and clearance impairment.

---

Interaction Scope

Category	Officially Documented Interaction Entities
Medicinal product categories with documented interactions	Other local anesthetic agents; Oxidizing agents; Vasopressor agents; Oxytocic drugs; Drugs of a similar chemical configuration (other ester-type local anesthetics, aminobenzoic acid, or its derivatives).
Mechanistic basis of interactions	Additive systemic toxic effects with other local anesthetics; Reduced clearance due to abnormal or reduced levels of plasma esterases.

---

Interaction Classifications

Official Interaction Statements

• Co-administration with other local anesthetic agents carries a documented risk of additive systemic toxic effects.
• The medicine is formally contraindicated for use with other ester-type local anesthetics or related derivatives like aminobenzoic acid.
• The use of vasopressor agents requires extreme caution when oxytocic drugs have been administered in the setting of spinal anesthesia due to the risk of severe persistent hypertension.
• Co-exposure to oxidizing agents increases the documented risk of methemoglobinemia.
• Exposure may be increased in patients with abnormal or reduced levels of plasma esterases, affecting metabolism and clearance.

---

This structure establishes prohibitions and specific contextual cautions for combinations that result in reinforced toxic effects or compromised systemic clearance, primarily addressing substance classes and physiological conditions.

The drug Dikain (tetracaine) is an ester local anesthetic. Its mechanism of action is primarily achieved through the modulation of nerve cell function via interruption of the electrochemical gradient necessary for signal transmission.

---

Modulation of Voltage-Gated Sodium Channels

Dikain acts within the domain of extbfneurotransmission by targeting extbfvoltage-gated sodium channels ( Na v channels) on nerve cell membranes. The drug directly extbfblocks the influx of sodium ions into the neuron, which is the critical early molecular step for generating an action potential. This engagement of the channel's mechanisms results in an extbfelevated membrane excitation threshold due to the sustained negative potential.

---

Suppression of Nerve Signal Propagation

This initial block initiates a mechanistic cascade that extbfsuppresses the signaling sequence for nerve impulse conduction. By preventing the necessary depolarization, Dikain extbfmodifies the propagation of electrical signals along the axon. The resulting physiological effect is the extbfreversible failure of action potential transmission, leading to an extbfabsence of propagated electrical activity within the targeted sensory neurons.

Administration Routes and Forms

The use of Дикаин (Tetracaine) is restricted exclusively to topical administration. The medication is applied either as a sterile ophthalmic solution to the surface of the eye or as a topical gel to the intact skin. This agent is not for injection or internal use, and its use is strictly confined to these external routes.

---

Dosing and Frequency Patterns

For ophthalmic use, the standard dose is one drop instilled into the eye(s) as required for a clinical procedure. This application is rapid-onset and short-acting, providing anesthesia that typically lasts for 10 to 20 minutes.

The 4% topical gel is applied to the skin in an amount not exceeding the contents of one tube per site, which covers up to 30 cm^2. The total dose must be strictly limited to a maximum of seven tubes over a 24-hour period. This single application is designed to provide sustained numbness lasting approximately 4 to 6 hours after removal.

---

Preparation and Contextual Conditions

The administration of the ophthalmic solution must occur under the direct supervision of a healthcare provider. The preparation protocols differ by formulation: the topical gel requires application under an occlusive dressing for a specific duration, usually 30 to 45 minutes, while the single-use ophthalmic containers must be discarded immediately after use. The topical gel is for use in pediatric patients over one month of age.

Research Evidence / Overview of Studies for Дикаин (Tetracaine)

---

Research Evidence for Topical Ophthalmic Anesthesia

The use of Дикаин (Tetracaine) for numbing the eye surface before minor clinical procedures was studied for outcomes related to physical discomfort. This research has primarily consisted of comparative controlled trials and systematic literature reviews. Researchers typically focused on measuring the onset time and the total duration of the anesthetic effect achieved on the surface of the eye. Studies have included both adult and pediatric patients undergoing procedures that require a short-term numbing effect.

Studies report measurements showing the onset of the numbing effect occurs quickly, with the onset was typically measured in seconds, and the duration generally lasting for approximately 10 to 20 minutes following application. The research highlights measurements consistent with the achievement of a temporary sensory block relevant to minor clinical interventions. The vast majority of the research is focused on characterizing the anesthetic block's physical properties, and the evidence base for rare or complex ocular conditions may be limited.

Research Evidence for Spinal Anesthesia

The injectable form of Tetracaine was studied for use in spinal anesthesia, which is a type of regional procedure intended to produce numbness for lower body surgery. Research in this area has utilized a framework of comparative Randomized Controlled Trials (RCTs). These studies examined outcomes such as the onset time, the total duration of the anesthetic effect (sensory blockade), and the accompanying effect on muscle function.

Studies report how the duration of the sensory blockade evolved in the observed surgical populations, with measured durations extending between 90 to 200 minutes. Findings describe that characteristics of the anesthetic block, including its spread and intensity, were observed in some studies to be comparable to other established agents depending on the specific formulation used.

Research Gaps and Remaining Uncertainties

A primary limitation across nearly all applications is the short-term focus, leaving long-term effects not fully established. For example, for the temporary use in managing acute corneal pain, some earlier trials had modest sample sizes, leading to findings that were mixed regarding statistical significance in pain scores. Data for certain groups, such as patients with severe or complex medical conditions, remain insufficient as these populations are often excluded from initial trials.

Key Studies & References

1. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list
2. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% - DailyMed
3. Tetracaine - StatPearls
4. A Review of the Effectiveness and Safety of Topical Anesthetics in Corneal Abrasions
5. Comparison of hyperbaric solutions of bupivacaine and tetracaine during continuous spinal anaesthesia

Common questions about Дикаин (FAQ)

---

Q: Can Дикаин cause drowsiness?

Potential systemic side effects of local anesthetics, which occur if too much of the drug is absorbed into the bloodstream, are classified within the Nervous System category in official product information. Symptoms associated with this category can include feeling dizzy or drowsy, and in rare, serious cases, may lead to loss of consciousness. The temporary sensory block itself is also a factor patients are advised to consider when performing activities.

---

Q: Is Дикаин safe for children?

Regulatory documents indicate that safety and effectiveness are established for pediatric patients across different age groups. However, the approved age of use can differ depending on the form of the medicine; for instance, the topical gel is officially approved for use in pediatric patients over one month of age. Use in children is typically restricted to administration under the direct supervision of a healthcare provider, in line with regulatory requirements.

---

Q: What happens if I use too much Дикаин?

Using more than the maximum recommended amount may lead to systemic toxicity, which means the drug affects the entire body. Initial symptoms of toxicity may include blurred vision, dizziness, or numbness around the mouth. If signs of toxicity occur, official product information describes a potential progression to more serious nervous system effects, and this situation requires the prompt evaluation of a healthcare professional.

---

Q: Does Дикаин need to be stored in the refrigerator?

Official storage instructions state that this medicine must be kept at temperatures between 15 C and 25 C (59 F and 77 F) and should not be frozen. This temperature range is generally consistent with normal room temperature storage.

---

Q: Are there any long-term side effects associated with Дикаин use?

Official safety warnings highlight that prolonged or repeated use of the ophthalmic solution is associated with the most serious risk: corneal epithelial toxicity. This specific condition can lead to progressive, permanent damage to the cornea (the clear front surface of the eye) and associated visual loss. The medicine is intended for short-term, temporary use only.

---

Q: Does using Дикаин affect driving or operating machinery?

Due to the possibility of systemic side effects, such as dizziness, blurred vision, or drowsiness, official documents advise caution. Patients are cautioned to consider how the temporary loss of sensation or any potential systemic effects might impact tasks such as driving or operating machinery, in alignment with warnings provided in the official labeling.

---

Q: Can Дикаин be used on broken or irritated skin?

The topical gel form is described in official product information for application to intact skin. Warnings generally caution against using the medicine over large areas or on skin that is raw or severely irritated, as this increases the likelihood of the drug being absorbed into the bloodstream, raising the risk of systemic side effects.

---

Q: Can I use Дикаин if I have kidney issues?

Official labeling does not provide specific dosing adjustments for patients with kidney issues, as the medicine is primarily cleared by enzymes in the blood. However, official guidance notes that pre-existing conditions affecting the nervous or circulatory systems may require careful assessment by a healthcare professional.

---

Q: Is Дикаин available over the counter?

Most formulations of this medicine, including the ophthalmic solution, are classified as prescription-only in many jurisdictions. Official guidelines also indicate that the drug is applied only by or under the direct supervision of a healthcare provider, which is a control measure for patient safety.

---

Q: Why do some people call Дикаин by a different name?

The active ingredient in Дикаин is Tetracaine, which is a generic chemical name. It is also known internationally by other names, such as Amethocaine or Pontocaine. These alternative names are based on different chemical naming conventions and trade names used by various pharmaceutical companies across international markets.

---

Q: Does Дикаин have an effect on blood pressure?

In cases where a sufficient amount of the medicine is absorbed into the bloodstream, it has been noted to potentially affect the Cardiovascular System. Furthermore, official interaction statements warn that using this medicine with certain vasopressor agents (drugs that increase blood pressure) requires caution due to a documented risk of severe persistent hypertension.

---

Q: What specific conditions or patient groups cannot use Дикаин?

The medicine is formally contraindicated, meaning it must not be used, if a patient has a known history of a severe hypersensitivity (allergic reaction) to the active substance itself. This absolute prohibition also extends to any other ester-type local anesthetics or related derivatives due to the chemical similarity.

---

Q: Are there research studies comparing Дикаин to other local anesthetics?

Research overviews confirm that the study of this medicine has involved comparative controlled trials. These studies often characterize the anesthetic effect achieved—such as its onset time and duration—and compare these measurements to those of other established local anesthetic agents used in similar clinical settings.

---

Q: What is the role of Дикаин in dentistry?

While the primary, well-documented uses are in ophthalmology and topical skin anesthesia, some clinical documents acknowledge that it may be used as part of a combination topical anesthetic preparation within the mouth. In this context, it is used to reduce discomfort prior to the injection of other local anesthetics for dental procedures.

---

Q: Can Дикаин be used for tattoos or cosmetic procedures?

The approved use is for providing topical or surface anesthesia for targeted clinical procedures. Although some warnings exist about the safe use of topical anesthetics in general for cosmetic procedures, an official, specific indication for use on tattoos is not documented in major regulatory sources.

---

Q: Can Дикаин interact with herbal supplements?

Official interaction lists primarily focus on other medicinal products and classes of drugs. General safety information suggests informing a healthcare professional of all products being used, including herbal supplements, to discuss the potential for interactions.

---

Q: What should I do if I forget to apply Дикаин?

For formulations that are intended for scheduled use, if an application is missed, it should be used as soon as the patient remembers. If it is nearly time for the next scheduled application, the missed dose should be skipped, and the patient should not use extra medicine to compensate. Following the labeled procedure for missed applications is important for managing the overall use of the product.

---

Q: Is it normal to feel a brief stinging when applying Дикаин?

Yes, regulatory documents categorize a brief, temporary stinging or burning sensation upon application as one of the most commonly reported local adverse reactions. This effect is often transient, meaning it is expected to pass quickly once the medicine is applied.

---

Q: Does Дикаин cause numbness in other parts of the body?

The medicine is a local anesthetic intended only to produce numbness in the specific, targeted area where it is applied. If the drug is absorbed systemically due to excessive use, symptoms of toxicity may include numbness of the tongue and around the mouth, which suggests an unwanted effect on other body parts.

---

Q: Are there any known drug interactions that make Дикаин less effective?

Official interaction statements primarily focus on combinations that increase the risk of side effects (additive toxicity). However, some official warnings suggest that co-administration with the breakdown product of other similar anesthetics, known as PABA, may inhibit its intended action, potentially reducing its overall effectiveness.

---

Q: Does Дикаин contain any preservatives or dyes?

Official product information, while focusing on the active component, advises patients to inform their healthcare professional if they have any known allergies to the excipients, preservatives, or dyes used in the formulation. All non-active ingredients, including preservatives and dyes, are listed in the full product label, which patients may review.

---

Q: What is the earliest research publication on Дикаин?

Historical summaries in scientific literature indicate that the active compound, Tetracaine, was first synthesized through chemical experiments in 1928. Its subsequent recognition and introduction into a clinical setting for use as an anesthetic occurred shortly after, around 1930.

---

Q: Why is a patch test sometimes mentioned before using Дикаин?

Since the medicine is formally contraindicated (must not be used) in patients with a history of hypersensitivity or contact allergy to the drug, a patch test may sometimes be used. This test is a clinical tool used by doctors to help identify or confirm an individual's specific sensitivity to Tetracaine or related compounds before application.

How to Store and Dispose of Дикаин (Tetracaine)

Official regulatory documents define specific conditions for the storage and disposal of Tetracaine Ophthalmic Solution to ensure stability and safety.

Storage Conditions

Tetracaine must be stored at a temperature between 15°C and 25°C (59°F and 77°F) and must be protected from light and not frozen. The container must be kept tightly closed during storage. The solution must not be used if it is cloudy, discolored, or contains crystals, as these indicate product degradation. This medicine must be stored out of the reach of children.

Disposal Instructions

Disposal of expired or unused Tetracaine should utilize an authorized drug take-back program where available. For single-use dispensers, any unused portion must be discarded immediately after administration. If a take-back program is unavailable, non-flushable medicines like Tetracaine should be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a container, and placed in the household trash.